Could a Lower Toll-like Receptor (TLR) and NF-κB Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron? by Ralf Kircheis, Oliver Planz

Get full text

Editorial: The role of toll-like receptors and their related signaling pathways in viral infection and inflammation by Oliver Planz, Ralf Kircheis

Get full text

The Role of Toll-like Receptors (TLRs) and Their Related Signaling Pathways in Viral Infection and Inflammation by Ralf Kircheis, Oliver Planz

Get full text

Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats by Yvonne Füll, Yvonne Füll, Christian Wallasch, Ashley Hilton, Oliver Planz, Oliver Planz

Get full text

COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF-κB Pathway by Ralf Kircheis, Manfred Schuster, Oliver Planz

Get full text

Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection by Sajjad Muhammad, Oliver Planz, Markus Schwaninger

Get full text

Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX^® and BacterX^® Pro by Julia Koch-Heier, Helen Hoffmann, Michael Schindler, Adrian Lussi, Oliver Planz

Get full text

The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs by André Schreiber, Benjamin Ambrosy, Oliver Planz, Sebastian Schloer, Ursula Rescher, Stephan Ludwig

Get full text

Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes by Hazem Hamza, Michael Ghosh, Markus W. Löffler, Hans-Georg Rammensee, Oliver Planz

Get full text

NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients by Ralf Kircheis, Emanuel Haasbach, Daniel Lueftenegger, Willm T. Heyken, Matthias Ocker, Oliver Planz

Get full text

Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans by Julia Koch-Heier, Julia Koch-Heier, Annika Schönsiegel, Annika Schönsiegel, Lara Maria Waidele, Lara Maria Waidele, Julian Volk, Julian Volk, Yvonne Füll, Christian Wallasch, Sebastian Canisius, Michael Burnet, Oliver Planz, Oliver Planz

Get full text

Adeno‐associated virus‐vectored influenza vaccine elicits neutralizing and Fcγ receptor‐activating antibodies by Daniel E Demminger, Lisa Walz, Kristina Dietert, Helen Hoffmann, Oliver Planz, Achim D Gruber, Veronika vonMessling, Thorsten Wolff

Get full text

Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002 by Hazem Hamza, Hazem Hamza, Mahmoud M. Shehata, Mahmoud M. Shehata, Ahmed Mostafa, Ahmed Mostafa, Ahmed Mostafa, Stephan Pleschka, Stephan Pleschka, Oliver Planz

Get full text

Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 t... by Gernot Rohde, Stephan Stenglein, Hans Prozesky, Ganesh Manudhane, Oana Sandulescu, Martin Bauer, Tim Overend, Winfried Koch, Dennis Neuschwander, Oliver Planz, Antoni Torres, Martin Witzenrath

Get full text

Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug by Karoline Droebner, Karoline Droebner, Karoline Droebner, Emanuel Haasbach, Sabine E. Dudek, Gerhard Scheuch, Karlheinz Nocker, Sebastian Canisius, Christina Ehrhardt, Georges von Degenfeld, Stephan Ludwig, Oliver Planz

Get full text

Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2 by Helen Hoffmann, Helen Hoffmann, Marina Ebensperger, Annika Schönsiegel, Annika Schönsiegel, Hazem Hamza, Hazem Hamza, Julia Koch-Heier, Julia Koch-Heier, André Schreiber, Stephan Ludwig, Michael Schindler, Oliver Planz

Get full text

Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. by Sharon M Barth, Christian M Schreitmüller, Franziska Proehl, Kathrin Oehl, Leonie M Lumpp, Daniel J Kowalewski, Moreno Di Marco, Theo Sturm, Linus Backert, Heiko Schuster, Stefan Stevanović, Hans-Georg Rammensee, Oliver Planz

Get full text

Establishment of a novel method to assess MEK1/2 inhibition in PBMCs for clinical drug development by Lara M. Schüssele, Lara M. Schüssele, Julia Koch-Heier, Julia Koch-Heier, Julian Volk, Julian Volk, Markus W. Löffler, Markus W. Löffler, Markus W. Löffler, Markus W. Löffler, Katharina Hoffmann, Regina M. Bruyns, Oliver Planz

Get full text

Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups by Hans-Georg Rammensee, Cécile Gouttefangeas, Sonja Heidu, Reinhild Klein, Beate Preuß, Juliane Sarah Walz, Annika Nelde, Sebastian P. Haen, Michael Reth, Jianying Yang, Ghazaleh Tabatabai, Hans Bösmüller, Helen Hoffmann, Michael Schindler, Oliver Planz, Karl-Heinz Wiesmüller, Markus W. Löffler

Get full text

4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses. by Carolin M Lieber, Megha Aggarwal, Jeong-Joong Yoon, Robert M Cox, Hae-Ji Kang, Julien Sourimant, Mart Toots, Scott K Johnson, Cheryl A Jones, Zachary M Sticher, Alexander A Kolykhalov, Manohar T Saindane, Stephen M Tompkins, Oliver Planz, George R Painter, Michael G Natchus, Kaori Sakamoto, Richard K Plemper

Get full text